Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immutep Limited filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose ADRs trade on Nasdaq and whose ordinary shares trade on ASX. Recent Form 6-K reports furnish ASX releases, quarterly activities reports and half-year financial information covering research and development spending, cash resources, clinical trial expenses and operating results.
The filings also record program-specific disclosures for eftilagimod alfa and IMP761, including TACTI-004, INSIGHT-003 and EFTISARC-NEO updates, FDA orphan drug designation in soft tissue sarcoma, development collaborations, and Nasdaq minimum-bid-price compliance notices. These documents describe clinical, regulatory, liquidity and capital-market matters for Immutep's LAG-3 immunotherapy portfolio.
Immutep Limited furnished a Form 6-K that attaches an exhibit summarizing translational data and significant pathologic response rates from its EFTISARC-NEO Phase II study. These results were highlighted in an oral presentation at the CTOS 2025 conference, and the filing formally submits that presentation information to U.S. investors.
Immutep Limited furnished a Form 6-K noting it received an A$4.6 million research and development tax incentive from the French Government. This inflow reflects government support tied to the company’s R&D activities.
The update is administrative in nature but adds cash to the business, as disclosed in the exhibit titled “Immutep Receives A$4.6 million R&D Tax Incentive from French Government.”
Immutep Limited filed its annual report on Form 20-F, outlining ongoing development of LAG‑3 immunotherapies and continued operating losses. The company reported a net loss of A$61.4 million for the fiscal year ended June 30, 2025, compared with A$42.7 million in 2024. Shares outstanding were 1,460,389,575 as of June 30, 2025. Its ADSs, each representing 10 ordinary shares, trade on Nasdaq as IMMP.
Immutep has no products approved for sale and is focused on clinical candidates including eftilagimod alfa (efti), IMP761, and partnered programs such as IMP701 (ieramilimab) with Novartis. The company has collaboration and supply agreements with Merck & Co. for pembrolizumab combination trials (Phase II and Phase III) and with Merck KGaA/Pfizer for avelumab (Phase I), and a regional license with EOC Pharma in China.
Management expects further losses as clinical activities expand and notes reliance on third‑party manufacturers, trial enrollment challenges, regulatory risks, and the need for additional financing. Financial statements are prepared under IFRS and presented in Australian dollars.
Immutep Limited filed a Form 6-K to furnish information about scientific presentations at a major oncology meeting. The filing notes an exhibit titled “Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer.”
Immutep Limited furnished a Form 6-K noting that the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma met its primary endpoint, with data presented at the ESMO Congress 2025.
The update is provided via Exhibit 99.1. Additional clinical details would be contained in the exhibit presentation materials.
Immutep Limited furnished a Form 6-K noting that the EFTISARC-NEO Phase II trial evaluating neoadjuvant efti in soft tissue sarcoma met its primary endpoint, with data presented at the ESMO Congress 2025.
The update is provided via Exhibit 99.1. Additional clinical details would be contained in the exhibit presentation materials.
Immutep Limited furnished a Form 6-K reporting an exhibit titled “Immutep Announces Successful Completion of FDA Project Optimus Requirements.” The notice identifies Exhibit 99.1 as the related material and is dated October 13, 2025.
Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.